Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma - PubMed (original) (raw)
Review
Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma
D Jones et al. Leuk Lymphoma. 2001 Feb.
Abstract
T cell non-Hodgkin's lymphomas (T-NHL) have traditionally been classified according to a variety of criteria including histological and clinical features, sites of involvement and etiologic agents. Except in select T-NHL types (e.g. CD30-positive anaplastic large cell lymphoma (ALCL)), immunophenotypic criteria are not used for routine subclassification of T-NHL. In this article. we outline the current models for classification and diagnosis of T cell tumors. We also briefly review the current understanding of non-neoplastic T cell subsets with regards to expression of activation markers belonging to the tumor necrosis factor receptor (TNFR) gene family. We summarize the currently available information on expression of these subset markers in T cell tumors, focusing on TNFR family members CD30 and CD134/OX40. CD134/OX40 expression is characteristic of certain entities (angioimmunoblastic lymphoma, angiocentric T-NHL) and a subset of T-NHLs of unspecified type, whereas CD30 expression is characteristic of ALCL and a largely non-overlapping subset of T-NHLs of unspecified type. Immunophenotypic stratification of T-NHL, using TNFR family members and other T cell subset-specific gene products, may provide a functional model for T-NHL classification as is currently the case for B cell tumors.
Similar articles
- The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma.
Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM. Jones D, et al. Blood. 1999 May 15;93(10):3487-93. Blood. 1999. PMID: 10233901 - T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
Coupland SE, Foss HD, Assaf C, Auw-Haedrich C, Anastassiou G, Anagnostopoulos I, Hummel M, Karesh JW, Lee WR, Stein H. Coupland SE, et al. Ophthalmology. 1999 Nov;106(11):2109-20. doi: 10.1016/S0161-6420(99)90492-X. Ophthalmology. 1999. PMID: 10571346 - Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL.
Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, Hamasaki M, Kawasaki C, Suzumiya J, Tomonaga M, Kikuchi M. Tsuchiya T, et al. Blood. 2004 Jan 1;103(1):236-41. doi: 10.1182/blood-2002-05-1352. Epub 2003 Sep 4. Blood. 2004. PMID: 12958063 - Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
Weisenburger DD, Anderson JR, Diebold J, Gascoyne RD, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Ullrich F, Armitage JO. Weisenburger DD, et al. Am J Hematol. 2001 Jul;67(3):172-8. doi: 10.1002/ajh.1102. Am J Hematol. 2001. PMID: 11391714 Review. - Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases.
Vang R, Medeiros LJ, Warnke RA, Higgins JP, Deavers MT. Vang R, et al. Mod Pathol. 2001 Nov;14(11):1093-9. doi: 10.1038/modpathol.3880442. Mod Pathol. 2001. PMID: 11706069 Review.
Cited by
- EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma.
Saber MM. Saber MM. J Immunol Res. 2022 Sep 12;2022:7219207. doi: 10.1155/2022/7219207. eCollection 2022. J Immunol Res. 2022. PMID: 36132984 Free PMC article. - A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy.
Washington LT, Huh YO, Powers LC, Duvic M, Jones D. Washington LT, et al. BMC Clin Pathol. 2002 Dec 10;2(1):5. doi: 10.1186/1472-6890-2-5. BMC Clin Pathol. 2002. PMID: 12475398 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources